Mylan gets OK to list stock in Israel as part of Perrigo pursuit; Eisai teams up to form GI specialist co.;

mylan

@FiercePharma: ICYMI: Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so. Article | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: UPDATED: Mylan hopes new show-and-tell will woo Perrigo shareholders. Story | Follow @CarlyHFierce

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

> Mylan ($MYL) has a go-ahead to list its shares on the Tel Aviv Stock Exchange as part of its hostile takeover effort for Perrigo ($PRGO). Report

> Japanese drugmaker Eisai and Ajinomoto have agreed to pool their resources in gastrointestinal pharmaceuticals to form a specialist company called EA Pharma. More

> Dietary supplements send 23,000 Americans to emergency rooms each year, a new federal study estimates. More

> The FDA has awarded $4.9 million to a Rutgers-led research team to expand continuous manufacturing techniques for pharma. Release

Medical Device News

@FierceMedDev: Intelesens gets FDA approval for its Zensor wearable vital signs device. More | Follow @FierceMedDev

@VarunSaxena2: California cutbacks: BD cuts 95 at CareFusion; Medtronic to cut 21 at distribution facility. Report | Follow @VarunSaxena2

@EmilyWFierce: Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C. FiercePharma report | Follow @EmilyWFierce

> Astute Medical to launch its diagnostic in China thanks to $20M investment from FosunPharma. Report

> 23andMe adds chapter to comeback story with $115M in funding. Article

Biotech News

@FierceBiotech: Zafgen finally breaks its silence, says it's probing death of a patient. Report | Follow @FierceBiotech

@JohnCFierce: Still trending -- Moderna's top scientist steps down amid a billion-dollar R&D push by @DamianFierce. Article | Follow @JohnCFierce

@DamianFierce: There is perhaps no greater tribute to Steve Jobs than obfuscating your business model and threatening your critics. WSJ story | Follow @DamianFierce

> Bristol-Myers inks a blockbuster $1.74B deal for an Opdivo combo drug. Story

> Galapagos moves third component of AbbVie-partnered CF therapy toward clinic. Report

> Hearing the call of a new quest, Third Rock answers with $52M biotech startup. Article

> FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand. More | Subscribe

CRO News

> INC bolsters its Phase I platform with new cardiac tech. Story

> Aesica bids to manage its clients' many contractors. More

> Cel-Sci lines up cash to fund its $50M suit against ex-partner inVentiv. Report

> CRO Frontage gets into agrochemicals with new service offering. Story

> PRA adds a biotech vet to its board amid an expansion effort. Article

Pharma Manufacturing News

> Myanmar offers incentives to lure its drug distributors into production. News

> Medline recalls 500-mg acetaminophen labeled as 325 mg. More

> Valeant's Bausch + Lomb plant getting $150M in investments, up to 200 jobs. Report

> Chinese company intends to build plant to produce Ebola vax. Article

> GSK selling its drug distribution biz in Romania. Story

Pharma Asia News

> China's State Council urges Suzhou Industrial Park to be more innovative. Story

> Japanese drug regulator opening Indian office. Item

> Lupin inks deal with Boehringer for diabetes drugs in India. News

> Superbug infections drop in China with new controls on antibiotic. Article

And Finally... The "herbal Viagra" pills linked to the hospitalization of former NBA star Lamar Odom, who was found unconscious Tuesday in a Nevada brothel, were the subject of an FDA warning two years ago. Story

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

Pfizer is using a "build-buy-partner" strategy to bring outside gene therapy candidates into its growing manufacturing space in North Carolina.